Indivior faces generic challenge

Investors will be keen to see what strategic goals the newly independent pharmaceutical group Indivior (INDV) publishes alongside its inaugural set of results next week. Not much is known about the entity spun out of consumer goods giant Reckitt Benckiser (RB.) in December.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now